SPOTLIGHT: Glaxo faces investor uprising


The natives are restless and are ready for a butchering. Inspired by lackluster stock performance, GlaxoSmithKline's institutional shareholders are demanding big changes--perhaps even a break-up of the company--according to London newspapers. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.